Actinium Pharmaceuticals, Inc. (ATNM) stock
ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.08−0.27 (-20.00%)
Close on Nov 18, 2026Market cap $33.96MP/E 3.0Yield –
Actinium Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Actinium Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $90.00K. For fiscal 2025 it was $90.00K, up 11.1% from the year before. The highest annual figure on record is $1.14M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.00K | +11.1% |
| FY2023 | Dec 31, 2023 | $81.00K | -92.1% |
| FY2022 | Dec 31, 2022 | $1.03M | -10.0% |
| FY2021 | Dec 31, 2021 | $1.14M | – |
| FY2011 | Dec 31, 2011 | $0 | – |
| FY2010 | Dec 31, 2010 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $35.00M | +77677.8% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $90.00K | -90.4% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $45.00K | -80.7% |
| Q2 FY2022 | Jun 30, 2022 | $45.00K | -83.1% |
| Q1 FY2022 | Mar 31, 2022 | $940.00K | +51.1% |
| Q4 FY2021 | Dec 31, 2021 | $23.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $233.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $266.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $622.00K | – |
See a number that looks wrong?